Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorman Broadb Regulatory News (NBB)

Share Price Information for Norman Broadb (NBB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.25
Bid: 8.50
Ask: 10.00
Change: 0.00 (0.00%)
Spread: 1.50 (17.647%)
Open: 9.25
High: 9.50
Low: 9.25
Prev. Close: 9.25
NBB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options to Directors

6 Jun 2016 07:00

NORMAN BROADBENT PLC - Grant of Options to Directors

NORMAN BROADBENT PLC - Grant of Options to Directors

PR Newswire

London, June 3

6 June 2016

Norman Broadbent plc

("Norman Broadbent" or "the Company")

Grant of Options to Directors

Norman Broadbent (AIM: NBB), a leading provider of executive search, leadership consultancy and complementary recruitment services announces that on 3 June 2016 the Company’s Remuneration Committee agreed to grant a total of 4,290,548 options to the Company's Executive Directors and certain employees under the rules of the Company's Enterprise Management Incentive Share Option Scheme 2007 (the "Scheme"). These options are exercisable at 13.5p per ordinary share, being the mid-market price at 12.00 noon on 3 June 2016.

The options granted under the Scheme are subject to various conditions. There are two tranches of options granted under the Scheme which are subject to different tiered vesting criteria related to: (i) share price or corporate performance; and (ii) time duration. Once vested, the options can be exercised at any time up to the seventh anniversary of the date of grant, being 3 June 2023.

For each Executive Director, 50 per cent. of the options granted vest subject to certain average share prices being achieved prior to 31 July 2020 and the remaining 50 per cent. vest subject to certain audited EBITDA figures being achieved for a financial year prior to 31 December 2019. EBITDA in this context is defined as earnings before interest, tax, depreciation and amortisation, excluding any non-recurring exceptional items as determined reasonable by the Remuneration Committee. Both tranches of options vest equally over three years from the date of issue, with the first such vesting date on the first anniversary of issue being 3 June 2017 and are subject to the continued employment of the relevant Executive Director. Accordingly, if all the performance criteria were achieved in year one, the earliest that the entire option pool could be exercised would be 3 June 2019.

The tiered average three month share prices which must be achieved for the vesting of the first tranche range between 22p and 70p per ordinary share. In addition, the audited EBITDA which must be achieved for the second tranche of options to vest ranges between approximately £600,000 and approximately £2 million. In any year where the EBITDA number achieved is less than 100 per cent. but greater than 80 per cent. of the relevant target, the number of options available for vesting would be adjusted pro rata.

The following table sets out the details of the options that have been granted to the Executive Directors:

DirectorShare Price Vesting OptionsEBITDA Vesting OptionsTotal number of options grantedTotal number of options heldPercentage of existing issued shares under optionPercentage of the fully diluted share capital*
Mike Brennan925,925925,9261,851,8511,851,85110.638.40
James Webber527,096527,0961,054,1921,054,1926.054.78
Total1,453,0211,453,0222,906,0432,906,04316.6913.18

* assuming that no further ordinary shares are issued by the Company between the date of this announcement and the exercise of the options.

Following the issue of the new options pursuant to the Scheme as detailed above, there are options outstanding over 4,628,492 ordinary shares, equivalent to 21 per cent. of the fully diluted share capital of the Company as at the date of this announcement, which are exercisable at exercise prices ranging from 13.5p to 70.00p per share. At the date of this announcement the Company has 17,416,487 ordinary voting shares in issue.

As the Executive Directors (Mike Brennan and James Webber) are Directors of the Company, the grant of the aggregate number of options to them constitutes a related party transaction as defined by the AIM Rules. The Independent Directors of the Company being Scanes Bentley, Brian Stephens and Richard Robinson, having consulted with Allenby Capital Limited, the Company's Nominated Adviser, consider that the terms of this option grant are fair and reasonable insofar as shareholders are concerned.

Scanes Bentley, Chairman of Norman Broadbent, commented:

“This options grant is a great opportunity for key team members across the Group to become beneficiaries of the future success of Norman Broadbent and, if the aggressive targets are achieved, will result in significant returns to all stakeholders. The Company’s major shareholders are supportive of this grant and feel that this creates appropriate incentivisation to now align all parties in driving profitability and value in the business over the coming years.”

For further information, please contact:

Norman Broadbent plc

Scanes Bentley/Mike Brennan/James Webber 020 7484 0000

Allenby Capital

Virginia Bull/Alex Brearley/ Simon Clements 020 7628 2200

Notes to Editors

Norman Broadbent plc is a leading provider of senior and board executive search and leadership consultancy and assessment services. Through AGP the Group also provides mezzanine level search and RPO solutions. Norman Broadbent Interim Management provides a dedicated senior interim management service focussed on enhanced client returns on investment and long term benefits. Social Media Search provides digital research to assist in house recruitment and social media management services.

For further information visit www.normanbroadbent.com

Date   Source Headline
25th Apr 20247:00 amRNSQ1 2024 Trading Update
24th Apr 20247:00 amRNSSmall Cap Awards nomination
15th Apr 20243:18 pmRNSNotification of major holdings
8th Apr 202412:11 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20244:01 pmRNSNotification of major holdings
28th Mar 20247:00 amRNSPosting of ARA & Notice of AGM
27th Mar 20247:00 amRNSFinal Results
26th Mar 20244:07 pmRNSNotification of major holdings
20th Mar 20241:36 pmRNSNotice of Results & Investor Presentation
18th Mar 20244:33 pmRNSNotification of major holdings
18th Mar 20244:04 pmRNSNotification of major holdings
12th Mar 20243:33 pmRNSAIM Rule 17 Schedule Two (g) Update
22nd Jan 20245:32 pmRNSNotification of Major Holdings
16th Jan 20247:00 amRNSTrading Update
21st Nov 202310:06 amRNSNotification of Major Holdings
20th Nov 202310:45 amRNSDirector/PDMR shareholding
15th Nov 20239:54 amRNSNotification of Major Holdings
15th Nov 20239:43 amRNSNotification of Major Holdings
10th Nov 20237:00 amRNSDirector/PCA Dealing
9th Nov 20232:25 pmRNSDirector/PDMR Shareholding
2nd Nov 20238:43 amRNSConversion Of Outstanding Convertible Loan Notes
12th Oct 20237:00 amRNSQ3 2023 Trading Update
10th Oct 202311:03 amRNSNotification of Major Holdings
9th Oct 20237:00 amRNSSurrender and Granting of Options
28th Jul 20237:00 amRNSGrant of Options
24th Jul 20237:00 amRNSInterim Results
11th Jul 20237:00 amRNSH1 2023 Trading Update
30th Jun 20237:00 amRNSSAYE Option Plan & Director Holding
29th Jun 20234:28 pmRNSResult of AGM
5th Jun 20237:00 amRNSPosting of Annual Report and Notice of AGM
1st Jun 20237:00 amRNSDirectorate changes
31st May 20237:00 amRNSFinal Results
22nd May 20237:00 amRNSQ1 2023 Trading Update
19th May 202312:55 pmRNSPartial Repayment of Convertible Loan Note
24th Jan 20237:00 amRNSTrading Update
10th Jan 20237:00 amRNSDirectorate Change
17th Nov 20224:42 pmRNSTR-1: Notification of major holdings
14th Nov 20227:00 amRNSIssue of Equity
1st Nov 20227:00 amRNSUpdate and Change of Board role
10th Oct 20225:30 pmRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSDirector Share Purchase
23rd Aug 20227:00 amRNSDirectorate Change
16th Aug 20227:00 amRNSInterim Results
29th Jul 20227:00 amRNSChange of Adviser
20th Jul 20224:08 pmRNSDirector/PDMR Dealing
11th Jul 20227:00 amRNSTrading Update
29th Jun 20223:15 pmRNSDirector/PDMR Shareholding
23rd Jun 202212:14 pmRNSResult of AGM
7th Jun 20228:59 amRNSHolding(s) in Company
25th May 20227:00 amRNSFinal 2021 Results and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.